Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.37M | 1.74M | 1.91M | 1.63M | 1.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.37M | 1.74M | 1.91M | 1.63M | 1.86M |
| Cost of Revenue | 9.50M | 25.84M | 3.82M | 29.14M | 17.14M |
| Gross Profit | -8.13M | -24.10M | -1.91M | -27.51M | -15.28M |
| SG&A Expenses | 25.50M | 10.64M | 11.45M | 13.77M | 31.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.99M | 36.48M | 38.88M | 42.91M | 48.87M |
| Operating Income | -33.62M | -34.74M | -36.97M | -41.28M | -47.01M |
| Income Before Tax | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M |
| EBIT | -33.62M | -34.74M | -36.97M | -41.28M | -47.01M |
| EBITDA | -30.56M | -31.51M | -33.69M | -37.95M | -42.20M |
| EPS Basic | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 |
| Normalized Basic EPS | -0.16 | -0.17 | -0.18 | -0.20 | -0.20 |
| EPS Diluted | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 |
| Normalized Diluted EPS | -0.16 | -0.17 | -0.18 | -0.20 | -0.20 |
| Average Basic Shares Outstanding | 119.25M | 119.00M | 118.53M | 118.38M | 117.79M |
| Average Diluted Shares Outstanding | 119.25M | 119.00M | 118.53M | 118.38M | 117.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |